Name: Update on #AVCT’s preCISION enabled proteasome inhibitor AVA3996
Uploaded: 2023-04-05T15:43:48.506675+00:00
Duration: 850 s
Channel: Vox Markets
Description: Update on #AVCT’s preCISION enabled proteasome inhibitor AVA3996

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/812/005812/video_lpghB0p.mp4#t=625

Vox Markets

Update on #AVCT’s preCISION enabled proteasome inhibitor AVA3996

Progress of AVA6000 clinical trial wrt safety, dosing regimes, efficacy and ultimate usage.

It’s currently a very busy & successful time for Avacta – a leading life sciences firm developing innovative, new cancer treatments & powerful diagnostics.
Hence, I was delighted today to catchup with CEO Alastair Smith, who took me through:

Progress of AVA6000 clinical trial wrt safety, dosing regimes, efficacy and ultimate usage. 00:00
Update on #AVCT’s preCISION enabled proteasome inhibitor AVA3996. 10:25

It’s currently a very busy &amp; successful time for Avacta – a leading life sciences firm developing innovative, new cancer treatments &amp; powerful diagnostics. Hence, I was delighted today to catchup with CEO Alastair Smith, who took me through:Progress of AVA6000 clinical trial wrt safety, dosing regimes, efficacy and ultimate usage. 00:00 Update on #AVCT’s preCISION enabled proteasome inhibitor AVA3996. 10:25

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/812/005812/video_lpghB0p.mp4